Guide Médicaments

109 articles

Tous les articles
Guide Médicaments

GLP-1 Dose Tracker: Log Your mg & Titration Schedule

A GLP-1 dose tracker logs which milligram you took on which date and follows your titration — Wegovy 0.25→2.4, Zepbound 2.5→15. See how to track and share it.

5 min de lecture
Guide Médicaments

Injection Tracker App for GLP-1: Features to Look For

Choosing an injection tracker app for GLP-1? Here are the must-have features — site-rotation body map, weekly reminders, dose log, missed-dose logic — and why it beats paper.

5 min de lecture
Guide Médicaments

Oral Wegovy Side Effects: Nausea & Warnings (2026)

Oral Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild-to-moderate and worst during dose increases. Because oral Wegovy is the same molecule as injectable Wegovy (semaglutide), it shares the *same* side-effect profile and the *same* serious warnings, including pancreatitis, gallbladder disease, and a boxed thyroid warning.

10 min de lecture
Guide Médicaments

Orforglipron Side Effects: Nausea, Warnings (2026)

Orforglipron's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — which are dose-dependent, tend to be worst around each dose increase, and usually settle as the body adapts. Rare but serious risks include a boxed warning for thyroid C-cell tumors plus pancreatitis and gallbladder disease, which need urgent medical care.

8 min de lecture
Guide Médicaments

Retatrutide Side Effects: Trial Data & Warnings 2026

In clinical trials, retatrutide's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — mostly mild-to-moderate and worst during dose escalation. Its triple-agonist design also produces two distinctive signals: abnormal skin sensations (dysesthesia) and a modest heart-rate increase. Retatrutide is investigational and available only through clinical trials — it cannot be prescribed.

7 min de lecture
Guide Médicaments

Semaglutide vs Tirzepatide: Which Is Right for You? (2026)

Tirzepatide (Mounjaro, Zepbound) acts on two hormones (GIP + GLP-1) and produced greater average weight loss in trials (~21%) than semaglutide (Ozempic, Wegovy, ~15%). But semaglutide has the longer track record and strong cardiovascular data. The "better" one depends on your goals, tolerance, cost, and prescriber.

4 min de lecture
Guide Médicaments

GLP-1 Side Effects: Ozempic, Wegovy & Tirzepatide Guide (2026)

The most common GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — and they are usually mild, most likely when starting or increasing the dose, and tend to ease within a few weeks. Rare but serious risks include pancreatitis, gallbladder problems, and severe delayed stomach emptying, which need urgent medical attention.

8 min de lecture
Guide Médicaments

How Much Does Wegovy & Ozempic Cost in 2026? Full Price Breakdown

Without insurance, Ozempic and Wegovy have list prices of roughly $970–$1,350 per month. But almost nobody pays that. Through the manufacturer's cash-pay pharmacy (NovoCare), self-pay prices in 2026 are about $349–$499/month for the injection and $149–$299/month for the newer oral pill — and with commercial insurance plus a savings card, eligible patients can pay as little as $0–$25 a month.

7 min de lecture
Guide Médicaments

Mounjaro Side Effects: Nausea, Sulfur Burps & Timeline (2026)

Mounjaro's most common side effects are gastrointestinal — nausea, diarrhea, decreased appetite, vomiting, and constipation — usually mild and worst during dose increases. Many users also report sulfur ("egg") burps. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

9 min de lecture
Guide Médicaments

Ozempic Side Effects: Nausea, Timeline & Warnings (2026)

Ozempic's most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.

9 min de lecture
Guide Médicaments

Semaglutide Side Effects: Ozempic, Wegovy & Rybelsus (2026)

Semaglutide's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Frequency depends on the product and dose: highest with Wegovy 2.4 mg (weight loss), lower with Ozempic and oral Rybelsus (diabetes). Rare serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

10 min de lecture
Guide Médicaments

Tirzepatide Side Effects: Mounjaro & Zepbound (2026)

The most common tirzepatide side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent medical care.

9 min de lecture
Guide Médicaments

Wegovy Side Effects: Nausea, Hair Loss & Timeline (2026)

Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Because Wegovy titrates to a higher 2.4 mg dose, these are reported more often than with Ozempic. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

10 min de lecture
Guide Médicaments

Zepbound Side Effects: Nausea, Hair Loss & Timeline (2026)

Zepbound's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Injection-site reactions and hair loss are also labeled. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.

11 min de lecture
Guide Médicaments

Les GLP-1 seuls ne suffisent pas — Le modèle « médicament + thérapie comportementale » recommandé par l'OMS/ADA, et les stades M0/M1/M2 de HAVIT

Les agonistes des récepteurs GLP-1 (Wegovy, Mounjaro, Zepbound) produisent une perte de poids moyenne de 15 à 22 % (STEP 1, SURMOUNT-1). Mais STEP 4 a rapporté une reprise de +11,6 %p un an après l'arrêt — environ 78 % de la perte de poids est revenue. L'OMS (2022) et les ADA Standards (2024) recommandent explicitement la thérapie comportementale en complément de la pharmacothérapie, et STEP 3 (JAMA 2021) a montré que la thérapie comportementale intensive en combinaison a permis une perte de poids près de 3× supérieure à la combinaison standard (−16 % vs −5,7 %). HAVIT structure cela en 3 stades — pré-médication (M0), adaptation (M1), maintien/arrêt (M2) — intégrant médicaments, préservation musculaire et apprentissage comportemental. HAVIT ne prescrit pas de GLP-1 ; la prescription, le dosage et l'arrêt restent du domaine du médecin.

14 min de lecture

Prêt à perdre du poids plus intelligemment ?

Tout ce qu'il faut pour perdre du poids, préserver vos muscles et créer de bonnes habitudes — dans une seule app dopée à l'IA.

Download on the App StoreGet it on Google Play

Téléchargement gratuit. Achats intégrés possibles.